Excision Biotherapeutics Appoints Franz Gerner as Chief Technology Officer & Head of Manufacturing

Excision BioTherapeutics appointed Franz Gerner, Ph.D., as Chief Technology Officer & Head of Manufacturing. Franz has more than 25 years of experience and before joining Excision, he served as VP, Technical Operations at Sio Gene Therapies, formerly Axovant Gene Therapies.

Excision Biotherapeutics is a private company focused on developing advanced gene-editing therapeutics to address the medical need for the treatment of life-threatening diseases caused by viral infections. It is based in Philadelphia, PA, and employs approximately 22 people.